Xiaotong Jia's questions to Altimmune Inc (ALT) leadership • Q3 2024
Question
Fiona, on behalf of Roger Song from Jefferies, asked whether the three additional indications for pemvidutide would be developed independently or as part of partnership discussions, and if the company's current cash runway extends to cover these new programs.
Answer
CEO Dr. Vipin Garg clarified that the new indications provide strategic optionality; Altimmune can develop them independently but they also enhance the value proposition for potential partners. He confirmed that the current cash runway, projected into H1 2026, is sufficient to fund the initial IND filings and Phase II proof-of-concept trials for these indications.